Short Interest in Gilead Sciences, Inc. (GILD) Grows By 25.9%
Gilead Sciences, Inc. (NASDAQ:GILD) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 16,844,547 shares, an increase of 25.9% from the July 14th total of 13,378,379 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 9,066,173 shares, the short-interest ratio is presently 1.9 days.
Shares of Gilead Sciences (NASDAQ GILD) opened at 72.70 on Friday. The company has a market cap of $94.94 billion, a PE ratio of 7.90 and a beta of 1.21. Gilead Sciences has a one year low of $63.76 and a one year high of $82.10. The stock’s 50 day moving average price is $72.31 and its 200-day moving average price is $68.76.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.98% and a return on equity of 57.17%. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the business posted $3.08 EPS. On average, analysts expect that Gilead Sciences will post $8.76 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.86%. Gilead Sciences’s payout ratio is currently 22.58%.
Several analysts have recently issued reports on the company. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. BMO Capital Markets restated a “hold” rating and set a $76.00 target price (up previously from $75.00) on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Cowen and Company restated an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research note on Wednesday, July 5th. Morgan Stanley restated an “equal weight” rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Finally, Deutsche Bank AG restated a “buy” rating and set a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Twelve analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $80.31.
In other news, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.
Several large investors have recently modified their holdings of GILD. Rockland Trust Co. raised its stake in shares of Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock valued at $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. raised its stake in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 154 shares during the last quarter. Berkshire Asset Management LLC PA bought a new stake in shares of Gilead Sciences during the first quarter valued at about $270,000. Sigma Planning Corp raised its stake in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 2,889 shares during the last quarter. Finally, Hollencrest Securities LLC raised its stake in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 4,210 shares during the last quarter. Institutional investors own 74.06% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/11/short-interest-in-gilead-sciences-inc-gild-grows-by-25-9.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.